Vaccinex (VCNX) AI Stock Analysis

• Market Cap: $1.84M
• Dividend Yield: N/A
• Average Volume (3M): 2.95K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.36
• Revenue Growth: 5.44%
• EPS Growth: 84.28%
• Country: US
• Employees: 23
• Sector: Healthcare
• Sector Strength: 54
• Industry: Biotechnology
• EPS (TTM): -10.12
• Shares Outstanding: 2,676,637
• 10 Day Avg. Volume: 2,467
• 30 Day Avg. Volume: 2,948
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 3.02
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 9.77
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Vaccinex is facing significant financial challenges with negative equity and reliance on external financing. The technical indicators show bearish trends, and valuation is constrained by ongoing losses and lack of dividends. These factors collectively result in a low overall stock score, highlighting high risk in the current investment environment.

Vaccinex Business Overview & Revenue Model

Company Description

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.

How the Company Makes Money

Vaccinex generates revenue primarily through collaborations and licensing agreements with pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development and regulatory goals, and royalties on future product sales. Additionally, Vaccinex may receive funding from government grants and research collaborations to support its clinical programs and technology development. The company's financial strategy focuses on advancing its clinical candidates through development stages to either bring them to market or out-license them to larger pharmaceutical organizations that can further develop and commercialize the products.

Vaccinex Financial Statement Overview

Summary

Vaccinex is facing significant financial challenges across all fronts. The income statement reveals consistent losses, the balance sheet shows financial instability with negative equity, and cash flows are predominantly negative. The company needs to address these issues to improve its financial health and stability.

Income Statement

The company exhibits a continuous decline in profitability, with a negative gross profit margin and net profit margin. Revenue growth is erratic, with significant fluctuations over the years. EBIT and EBITDA margins are deeply negative, indicating operational challenges in achieving profitability.

Balance Sheet

The balance sheet shows negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is not meaningful due to negative equity, but the company has a relatively low level of total debt. The equity ratio is negative, reflecting a severe financial risk profile.

Cash Flow

Cash flow from operations is consistently negative, indicating a struggle to generate cash from core operations. Free cash flow is also negative, although there is a noticeable reduction in the negative free cash flow trend over the recent period, suggesting a slight improvement.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
570.00K	100.00K	900.00K	50.00K	523.00K
	Gross Profit
570.00K	-107.00K	731.00K	48.00K	324.00K
	EBIT
-22.89M	-19.91M	-22.49M	-28.33M	-32.02M
	EBITDA
-19.75M	-19.61M	-21.40M	-28.05M	-31.61M
	Net Income Common Stockholders
-20.25M	-19.72M	-23.23M	-29.31M	-32.02M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.53M	6.39M	8.59M	10.60M	2.78M
	Total Assets
3.63M	7.98M	9.84M	11.70M	4.60M
	Total Debt
247.00K	485.00K	390.00K	9.21M	0.00
	Net Debt
-1.29M	-5.91M	-8.20M	-1.39M	-2.78M
	Total Liabilities
5.94M	2.78M	2.43M	14.31M	6.88M
	Stockholders Equity
-2.31M	5.19M	7.41M	-26.57M	-26.24M
Cash Flow		Free Cash Flow
-17.30M	-19.17M	-25.33M	-28.94M	-30.79M
	Operating Cash Flow
-17.23M	-19.07M	-25.30M	-28.65M	-30.71M
	Investing Cash Flow
-67.00K	-99.00K	-32.00K	-290.00K	14.07M
	Financing Cash Flow
12.45M	16.98M	23.32M	36.76M	13.80M

Vaccinex Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.69
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VCNX, the sentiment is Positive. The current price of 0.69 is below the 20-day moving average (MA) of 0.82, below the 50-day MA of 0.80, and below the 200-day MA of 2.63, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 54.09 is Neutral, neither overbought nor oversold. The STOCH value of 53.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VCNX.

Vaccinex Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.21B	3.55	-41.91%	2.83%	15.12%	0.42%
SCNI	52 Neutral	$2.39M	9.19	138.38%	―	―	―
VCNX	39 Underperform	$1.84M	―	1406.28%	―	5.44%	84.28%
CNSP	32 Underperform	$3.24M	―	-1703.39%	―	―	90.33%
QLGN	31 Underperform	$2.54M	―	367.65%	―	-100.00%	69.07%
GLTO	29 Underperform	$3.94M	―	-91.62%	―	―	48.81%
NCNA	28 Underperform	$2.29M	―	-183.07%	―	―	35.70%